FDG-PET imaging in the management of non-small-cell lung cancer

被引:9
|
作者
Salminen, E
Mac Manus, M
机构
[1] Turku Univ Hosp, Dept Radiotherapy & Oncol, FIN-20520 Turku, Finland
[2] Peter MacCallum Canc Inst, Melbourne, Vic 3000, Australia
关键词
FDG-PET; non-small-cell lung cancer; outcome; staging; treatment;
D O I
10.1093/annonc/mdf106
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Lung cancer is currently the leading cause of cancer-related death in both men and women in most Western countries. Tumour stage is the strongest prognostic factor and the most important parameter guiding treatment decision making. Metabolic positron emission tomography imaging with fluorodeoxyglucose (FDG-PET) has consistently proved superior to conventional imaging for staging of non-small-cell lung cancer and provides information of greater prognostic significance than can be obtained using conventional approaches. FDG-PET has been approved in the USA. Germany and the UK as a basic and invaluable tool in the management of lung cancer.
引用
收藏
页码:357 / 360
页数:4
相关论文
共 50 条
  • [31] FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology
    Ryu, JS
    Choi, NC
    Fischman, AJ
    Lynch, TJ
    Mathisen, DJ
    LUNG CANCER, 2002, 35 (02) : 179 - 187
  • [32] Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer
    Sunaga, Noriaki
    Oriuchi, Noboru
    Kaira, Kyoichi
    Yanagitani, Noriko
    Tomizawa, Yoshio
    Hisada, Takeshi
    Ishizuka, Tamotsu
    Endo, Keigo
    Mori, Masatomo
    LUNG CANCER, 2008, 59 (02) : 203 - 210
  • [33] FDG-PET SUVmax Does Not Correlate with Glucose Metabolism in Non-Small Cell Lung Cancer
    Kernstine, Kemp
    Faubert, Brandon
    Hensley, Christopher
    Cai, Ling
    Torrealba, Jose
    Oliver, Dwight
    Lenkinski, Robert
    Malloy, Craig
    Deberardinis, Ralph
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S554 - S554
  • [34] Surgical management of non-small-cell lung cancer
    Bamousa, Ahmed
    AlKattan, Khaled
    ANNALS OF THORACIC MEDICINE, 2008, 3 (06) : S82 - S88
  • [35] FDG PET/CT as theranostic imaging in diagnosis of non-small cell lung cancer
    Kirienko, Margarita
    Gallivanone, Francesca
    Sollini, Martina
    Veronesi, Giulia
    Voulaz, Emanuele
    Antunovic, Lidjia
    Leonardi, Lorenzo
    Testanera, Giorgio
    Castiglioni, Isabella
    Chiti, Arturo
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2017, 22 : 1713 - 1723
  • [36] State-of-the-art FDG-PET imaging of lung cancer
    Gilman, MD
    Aquino, SL
    SEMINARS IN ROENTGENOLOGY, 2005, 40 (02) : 143 - 153
  • [37] Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study
    Verboom, P
    van Tinteren, H
    Hoekstra, OS
    Smit, EF
    van den Bergh, JHAM
    Schreurs, AJM
    Stallaert, RALM
    van Velthoven, PCM
    Comans, EFI
    Diepenhorst, FW
    van Mourik, JC
    Postmus, PE
    Boers, M
    Grijseels, EWM
    Teule, GJJ
    Uyl-de Groot, CA
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2003, 30 (11) : 1444 - 1449
  • [38] Staging of Non-Small-Cell Lung Cancer
    Akhurst, Tim
    PET CLINICS, 2018, 13 (01) : 1 - +
  • [39] Decision-tree sensitivity analysis for cost-effectiveness of FDG-PET in patients with non-small-cell lung carcinoma
    Kosuda, S
    Ichihara, K
    Watanabe, M
    Kobayashi, H
    Kusano, S
    POSITRON EMISSION TOMOGRAPHY IN THE MILLENNIUM, 2000, 1197 : 187 - 190
  • [40] Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study
    Paul Verboom
    Harm van Tinteren
    Otto S. Hoekstra
    Egbert F. Smit
    Jan H. A. M. van den Bergh
    Ad J. M. Schreurs
    Roland A. L. M. Stallaert
    Piet C. M. van Velthoven
    Emile F. I. Comans
    Fred W. Diepenhorst
    Johan C. van Mourik
    Pieter E. Postmus
    Maarten Boers
    Els W. M. Grijseels
    Gerrit J. J. Teule
    Carin A. Uyl-de Groot
    European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30 : 1444 - 1449